LCS101

has antineoplastic activity; consists of Astragalus membranaceus, Poriae cocos, Atractylodes macrocephala, Lycium chinense, Ligustrum lucidum, Paeonia lactiflora, Paeonia obovata, Citrus reticulata, Ophiopogon japonicus, Milletia reticulata, Oldenlandia diffusa, Scutellaria barbata, Prunella vulgaris, and Glehnia littoralis

Networked: 7 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Maimon, Yair: 6 articles (03/2019 - 01/2011)
2.	Samuels, Noah: 6 articles (03/2019 - 01/2011)
3.	Berger, Raanan: 3 articles (03/2019 - 01/2015)
4.	Cohen, Zoya: 3 articles (03/2019 - 01/2015)
5.	Shoham, Jacob: 2 articles (01/2013 - 01/2011)
6.	Rosenthal, David S: 1 article (12/2018)
7.	Yang, Peiying: 1 article (01/2015)
8.	Yoeli-Lerner, Merav: 1 article (01/2015)
9.	Melnick, Steven J: 1 article (01/2013)
10.	Pavlovsky, Anya: 1 article (01/2013)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/2013 - "The effects of LCS101 on clinical outcomes in breast cancer should be tested further using randomized controlled trials." 01/01/2015 - "LCS101 was also found to induce PARP-1 reduction in breast cancer cells, with no effect on non-tumorigenic breast epithelial cells. " 01/01/2011 - "Sixty-five breast cancer patients were recruited, with 34 allocated to LCS101 and 31 allocated to placebo treatment. " 01/01/2011 - "This prospective, controlled study evaluated the safety, tolerability, and efficacy of the mixture of botanical compounds known as LCS101 in preventing chemotherapy-induced hematological toxicity in breast cancer patients. " 01/01/2012 - "Letter to the editor regarding "A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer" by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202)."
2.	Neoplasms (Cancer) 03/01/2019 - "The addition of the botanical formula LCS101 to irradiated cancer cells results in an apparent additive effect, most likely through a ROS-mediated mechanism. " 12/01/2018 - "LCS101 exhibits multi-targeted effects, with significant implications for cancer care. " 12/01/2018 - "Botanical Formula LCS101: A Multi-Targeted Approach to Cancer Care." 01/01/2015 - "The effects of LCS101 were tested on a number of cancer cell lines (breast, MCF7, MDA-MB‑231; colorectal, HCT116; prostate, PC-3, DU-145) and on non-tumorigenic normal human epithelial cells (breast, MCF10A; prostate, EP#2). " 01/01/2013 - "Immunomodulatory effects of the botanical compound LCS101: implications for cancer treatment."
3.	Prostatic Neoplasms (Prostate Cancer) 12/01/2018 - "Selective Anticancer Effects: In vitro LCS101 demonstrated selective growth inhibition (on XTT viability assay) in human breast and prostate cancer cell lines, without any harmful effects on normal human epithelial cells. " 01/01/2015 - "LCS101 selectively induced cell death in breast, colon and prostate cancer cell lines, as measured by XTT assay. " 03/01/2019 - "The addition of LCS101 to MCF7 (breast) and DU-145 (prostate) cancer cell lines resulted in a dose-dependent increase in the antiproliferative effects of radiation treatment. "
4.	Vomiting 12/01/2018 - "Symptom Relief and Quality of Life: Clinical research shows that patients taking LCS101 during chemotherapy are less likely to report symptoms such as fatigue, pain, nausea and vomiting. "
5.	Osteosarcoma (Osteogenic Sarcoma) 03/01/2019 - "Incremental doses of LCS101 were added to breast adenocarcinoma (MCF7), prostate (DU145), transitional cell bladder carcinoma (T24), pancreatic epithelioid carcinoma (PANC-1), and osteosarcoma (U20S) cell lines 4 h after single-dose irradiation (range 0.5-4 Gy). "

Related Drugs and Biologics

1.	Fluorouracil (Carac)
2.	Doxorubicin (Adriamycin)
3.	Anthracyclines
4.	taxane

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Radiotherapy